Ex-FDA Division Director Joins Javelin Pharmaceuticals

September 9, 2005

Applied Clinical Trials

Javelin Pharmaceuticals, Inc. (OTC BB: JVPH) has named Curtis Wright, IV, MD, MPH as Vice President of Risk Management and Regulatory Affairs.

New York, NY– September 7, 2005 – Javelin Pharmaceuticals, Inc. (OTC BB: JVPH) has named Curtis Wright, IV, MD, MPH as Vice President of Risk Management and Regulatory Affairs. Dr. Wright, a renowned authority on clinical risk assessment, served at the FDA from 1989 to 1997 in its Center for Drug Evaluation and Research. Upon leaving government service he became Vice President for Clinical and Regulatory Affairs at Adolor Corporation. In 1998 he joined Purdue Pharma where he held a series of senior positions in medical affairs and medical research-ultimately becoming Executive Director for Risk Assessment and Health Policy.

While at the FDA, Dr. Wright's positions included the following: Medical Review Officer, Acting Director of the Pilot Drug Division, Team Leader for Analgesics and Addictive Drugs, and Acting and then Deputy Director of Anesthetics, Analgesics and Drug Abuse. He has also served on the faculty of the Uniformed Services University of Health Sciences in Bethesda, Maryland. Other notable positions include staff physician at the Bethesda Naval Hospital where he also served as Acting Head of its Emergency Services, and Battalion Surgeon with the 3rd Marine Division at Okinawa.

Dr. Daniel Carr, Chief Executive Officer commented, "Risk management and regulatory issues are crucial to current analgesic drug development, especially for our product candidates whose active ingredients have proven efficacy and huge safety databases. Dr. Wright's unparalleled depth of knowledge in assessing and managing the risk of patients, products and the research franchise reflects his prior service as director of the same FDA division with which we are now working. Furthermore, his military background provides first-hand familiarity with the needs of our Army stakeholders and supporters who may well ultimately become our customers. We are delighted to have this talented expert join Javelin's development team."

The author of a number of peer-reviewed publications on drug development as well as substance abuse, Dr. Wright has lectured extensively on these topics. He is the recipient of many awards and honors including election to Alpha Omega Alpha, the medical honor society; the FDA Center Director's Award for Exemplary Contribution; the Health and Human Services Secretary's Award for Distinguished Service; and Outstanding Clinical Pharmacology Professor at the Uniformed Services University of the Health Sciences.

Dr. Wright graduated from Haverford College and completed his post-bachelor work at the Foundation for Advanced Education in the Sciences at Trinity College, and obtained his medical degree from George Washington University. He went on to receive a Masters of Public Health from Johns Hopkins, where he served as senior clinical fellow and research fellow for the departments of medicine and psychiatry, respectively.

About Javelin Pharmaceuticals

Javelin Pharmaceuticals (formerly Intrac, Inc.) is a specialty pharmaceutical company, applying innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information please visit the website www.javelinpharmaceuticals.com or www.idds.com.

Related Content:

News